Tokyo, Japan

Ryuichi Sekioka

USPTO Granted Patents = 4 


 

Average Co-Inventor Count = 10.3

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2015-2025

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):

Title: Ryuichi Sekioka: Innovator in Therapeutic Compounds

Introduction

Ryuichi Sekioka is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of therapeutic compounds. With a total of 4 patents to his name, Sekioka's work has the potential to impact various medical treatments.

Latest Patents

One of Sekioka's latest patents focuses on "Bicyclic 1,4-diazepanones and therapeutic uses thereof." This patent provides compounds of a specific formula, including stereoisomers and pharmaceutically acceptable salts. The invention outlines methods for using these compounds to treat diseases and disorders that respond to the modulation of skeletal sarcomere contractility. This innovative approach highlights Sekioka's commitment to advancing medical science through his research.

Career Highlights

Throughout his career, Ryuichi Sekioka has worked with notable companies such as Cytokinetics, Inc. and Astellas Pharma GmbH. His experience in these organizations has allowed him to collaborate with leading experts in the pharmaceutical industry, further enhancing his contributions to the field.

Collaborations

Sekioka has had the opportunity to work alongside talented individuals, including Bradley Paul Morgan and Chris Evans. These collaborations have likely enriched his research and development efforts, fostering an environment of innovation.

Conclusion

Ryuichi Sekioka is a distinguished inventor whose work in therapeutic compounds is paving the way for advancements in medical treatments. His patents and collaborations reflect a dedication to improving healthcare through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…